Literature DB >> 7728776

The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells.

T Okamoto1, M Harada, Y Shinomiya, G Matsuzaki, K Nomoto.   

Abstract

To establish an efficient cell-culture system for adoptive immunotherapy, we attempted to use lipopolysaccharide(LPS)-activated B cells (LPS blasts) as costimulatory-signal-providing cells in the in vitro induction of antitumor effector cells. Both normal and tumor-draining lymph node cells were efficiently activated by both anti-CD3 monoclonal antibody (mAb) and LPS blasts, and subsequently expanded by a low dose of interleukin-2 (IL-2; anti-CD3 mAb and LPS blasts/IL-2). The expanded cells were predominantly CD8+ T cells and showed a low level of tumor-specific cytotoxic T lymphocyte (CTL) activity. The adoptive transfer of B16-melanoma-draining lymph node cells expanded by anti-CD3 mAb and LPS blasts/IL-2 showed significant antitumor effect against the established metastases of B16 in combination with intraperitoneal injections of IL-2. This treatment cured all B16-bearing mice. In addition, these mice also showed tumor-specific protective immunity against B16 at the rechallenge. Considering that activated B cells express several kinds of costimulatory molecules, these findings thus indicate an efficacy of costimulation that is derived from activated B cells for the in vitro induction of tumor-specific CTL, in co-operation with anti-CD3 mAb. The culture system presented here may thus be therapeutically useful, providing potent effectors for adoptive immunotherapy against various types of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728776     DOI: 10.1007/bf01517349

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.

Authors:  S Shu; T Chou; S A Rosenberg
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

3.  Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen.

Authors:  Y Liu; B Jones; W Brady; C A Janeway; P S Linsley; P S Linley
Journal:  Eur J Immunol       Date:  1992-11       Impact factor: 5.532

4.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

5.  Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.

Authors:  H Yoshizawa; A E Chang; S Y Shu
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

Review 6.  Costimulation of T cells for tumor immunity.

Authors:  L Chen; P S Linsley; K E Hellström
Journal:  Immunol Today       Date:  1993-10

7.  Early appearance and activation of natural killer cells in tumor-infiltrating lymphoid cells during tumor development.

Authors:  S Kurosawa; G Matsuzaki; M Harada; T Ando; K Nomoto
Journal:  Eur J Immunol       Date:  1993-05       Impact factor: 5.532

Review 8.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

9.  Heat-stable antigen is a costimulatory molecule for CD4 T cell growth.

Authors:  Y Liu; B Jones; A Aruffo; K M Sullivan; P S Linsley; C A Janeway
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  3 in total

1.  Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.

Authors:  M Harada; T Okamoto; K Omoto; K Tamada; M Takenoyama; C Hirashima; O Ito; G Kimura; K Nomoto
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta.

Authors:  K Tamada; M Harada; O Ito; M Takenoyama; T Mori; G Matsuzaki; K Nomoto
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.

Authors:  K Tamada; M Harada; T Okamoto; M Takenoyama; O Ito; G Matsuzaki; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.